Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an ADC consisting of a MMAE payload conjugated to a human mAb targeting the tumor antigen 5T4; and XL495, a small molecule inhibitor of PKMYT1. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent Pharma Solutions, Inc.; Iconic Therapeutics, Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Exelixis Inc.

Exelixis ($EXEL) announced an update on their ongoing clinical study. Exelixis has launched a new Phase 2 trial called “A Phase 2, Single-Arm, Mult...

Exelixis Advances Zanzalintinib Into Phase 2 Meningioma Trial, Signaling Pipeline Expansion

In a report released yesterday, from Guggenheim maintained a Hold rating on Exelixis. The company’s shares closed yesterday at $48.70. The word on ...

Guggenheim Remains a Hold on Exelixis (EXEL)

Exelixis (($EXEL)) has held its Q1 earnings call. Read on for the main highlights of the call. Exelixis struck an upbeat tone on its latest earning...

Exelixis Earnings Call Highlights Growth And ZANZA Risks

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lemaitre Vascular (LMAT), Henry Schein (HSIC) and Exelixis (EXEL)...

Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (LMAT), Henry Schein (HSIC) and Exelixis (EXEL)

Exelixis ( ($EXEL) ) just unveiled an announcement. On May 5, 2026, Exelixis reported first quarter 2026 revenues of $610.8 million, up from $555.4...

Market Cap	$11.31B	P/E Ratio	15.83
52W High	$51.63	52W Low	$33.76
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	71.6%	52W Position	90.1%
Overall Score	66	Value Score	70
Quality Score	68	Technical Score	60

EPS Current Est	$3.15	EPS Next Est	$3.69
EPS Growth Est	+17.1%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	EXEL	$49.86	-0.58%	1.06M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	EXEL	$49.86	-0.6%	1.06M
3
4
5
6

EXEL

EXEL

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Exelixis Inc. Data in Excel

Get Exelixis Inc. Data in Excel